Coauthorship and institutional collaborations on cost-effectiveness analyses: A systematic network analysis

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Catalá López, Ferrán ^a,b,c   Alonso Arroyo, Adolfo ^d,e   Aleixandre Benavent, Rafael ^d   Ridao, Manuel ^a,f   Bolaños, Máxima ^d   García Altés, Anna ^b   Sanfélix Gimeno, Gabriel ^a   Peiró, Salvador ^a,b  

^a Centro Superior de Investigacion en Salud Publica CSISP   (Spain)

^b Fundacion Instituto de Investigacion en Servicios de Salud   (Spain)

^c Department of Medicines for Veterinary Use   (Spain)

^d UNIVERSITY OF VALENCIA   (Spain)

^e UNIVERSITY OF VALENCIA   (Spain)

^f INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; COMPUTER PROGRAM; COST EFFECTIVENESS ANALYSIS; DISABILITY ADJUSTED LIFE YEAR; DRUG INDUSTRY; MEDICAL DECISION MAKING; MEDICAL LITERATURE; OUTCOME ASSESSMENT; PRIMARY MEDICAL CARE; PUBLIC HOSPITAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SPAIN; SYSTEMATIC REVIEW;

EID: 84872621588     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038012     Document Type: Article

References (44)

1. Bekelman JE, Li Y, Gross CP, (2003) Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA. 289 (4): 454-65.
2. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B, (2003) Evidence b(i)ased medicine-selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ. 326 (7400): 1171-3.
3. Lesser LI, Ebbeling CB, Goozner M, Wypij D, Ludwig DS, (2007) Relationship between funding source and conclusion among nutrition-related scientific articles. PloS Med. 4 (1): e5.
4. Bero L, Oostvogel F, Bacchetti P, Lee K, (2007) Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others. PLoS Med. 4: e184.
5. Bell CM, Urbach DR, Ray JG, Bayoumi A, Rosen AB, et al. (2006) Bias in published cost effectiveness studies: systematic review. BMJ. 332 (7543): 699-703.
6. Garattini L, Koleva D, Casadei G, (2010) Modeling in pharmacoeconomic studies: funding sources and outcomes. Int J Technol Assess Health Care. 26: 330-3.
7. Sculpher MJ, Pang FS, Manca A, Drummond MF, Golder S, et al. (2004) Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol Assess 8: iii-iv, 1-192.
8. Raftery JP, (2008) Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand. Med J Aust. 188: 26-8.
9. Laupacis A, (2006) Economic evaluations in the Canadian common drug review. Pharmacoeconomics. 24: 1157-62.
10. Antoñanzas F, Oliva J, Pinillos M, Juàrez C, (2007) Economic aspects of the new Spanish laws on pharmaceutical preparations. Eur J Health Econ. 8: 297-300.
11. Real Decreto-Ley 9/2011, de 19 de agosto, de medidas para la mejora de la calidad y cohesión del Sistema Nacional de Salud, de contribución a la consolidación fiscal, y de elevación del importe máximo de los avales del Estado para, (2011) BOE Núm. 200. Sábado 20 de agosto de 2011.
12. Peiró S, Meneu R, Sanfélix-Gimeno G, Catalá-López F, (2011) Mejorar la prescripción y, de paso, el gasto farmacéutico. Elementos para las políticas prácticas. In: Ortún V, editor. La refundación de la atención primaria. Madrid: Springer Healthcare. 2 Available: http://www.upf.edu/catedragrunenthalsemg/_pdf/Cap_5.pdf. Accessed 2012 Jan.
13. Bales ME, Johnson SB, Keeling JW, Carley KM, Kunkel F, et al. (2011) Evolution of coauthorship in public health services and systems research. Am J Prev Med. 41: 112-7.
14. Newman ME, (2004) Coauthorship networks and patterns of scientific collaboration. Proc Natl Acad Sci USA. 101(Suppl1) pp. 5200-5.
15. Blanchet K, James P, (2011) How to do (or not to do)... a social network analysis in health systems research. Health Policy Plan. [Epub ahead of print].
16. González-Alcaide G, Aleixandre-Benavent R, Navarro-Molina C, Valderrama-Zurián JC, (2008) Coauthorship networks and institutional collaboration patterns in reproductive biology. Fertil Steril. 90: 941-56.
17. Valderrama-Zurián JC, González-Alcaide G, Valderrama-Zurián FJ, Aleixandre-Benavent R, Miguel-Dasit A, (2007) Coauthorship networks and institutional collaboration in Revista Española de Cardiología publications. Rev Esp Cardiol. 60: 117-30.
18. Catalá-López F, García-Altés A, Alvarez-Martín E, Gènova-Maleras R, Morant-Ginestar C, et al. (2011) Burden of disease and economic evaluation of healthcare interventions: are we investigating what really matters? BMC Health Serv Res. 11: 75.
19. Catalá-López F, García-Altés A, (2010) Economic evaluation of healthcare interventions during more than 25 years in Spain (1983-2008). Rev Esp Salud Publica. 84: 353-69.
20. Gold MR, Siegel JE, Russell LB, Weinstein MC, (1996) Cost-effectiveness in Health and Medicine. Oxford, UK Oxford University Press.
21. Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, et al.eds. (2006) Disease Control Priorities in Developing Countries. New York Oxford University Press and The World Bank.
22. Batagelj V, Mrvar A, (2010) Pajek 1.28. Program for large network analysis. Ljubljana University of Ljubljana.
23. Mar J, Rodríguez-Artalejo F, (2001) Which is more important for the efficiency of hypertension treatment: hypertension stage, type of drug or therapeutic compliance? J Hypertens. 19: 149-55.
24. Mar J, Rueda JR, Durán-Cantolla J, Schechter C, Chilcott J, (2003) The cost-effectiveness of nCPAP treatment in patients with moderate-to-severe obstructive sleep apnoea. Eur Respir J. 21: 515-22.
25. Mar J, Begiristain JM, Arrazola A, (2005) Cost-effectiveness analysis of thrombolytic treatment for stroke. Cerebrovasc Dis. 20: 193-200.
26. Greenberg D, Rosen AB, Wacht O, Palmer J, Neumann PJ, (2010) A bibliometric review of cost-effectiveness analyses in the economic and medical literature: 1976-2006. Med Decis Making 30: 320-7.
27. Patsopoulos NA, Analatos AA, Ioannidis JPA, (2006) Origin and funding of the most frequently cited papers in medicine: database analysis. BMJ. 332: 1061-4.
28. Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL, (1999) Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA. 282 (15): 1453-7.
29. Knox KS, Adams JR, Djulbegovic B, Stinson TJ, Tomor C, et al. (2000) Reporting and dissemination of industry versus non-profit sponsored economic analyses of six novel drugs used in oncology. Ann Oncol. 11 (12): 1591-5.
30. Hartmann M, Knoth H, Schulz D, Knoth S, Meier-Hellmann A, (2003) Industry-sponsored economic studies in critical and intensive care versus studies sponsored by nonprofit organizations. J Intensive Care Med. 18 (5): 265-8.
31. Hartmann M, Knoth H, Schulz D, Knoth S, (2003) Industry-sponsored economic studies in oncology vs studies sponsored by nonprofit organisations. Br J Cancer. 89 (8): 1405-8.
32. Baker CB, Johnsrud MT, Crismon ML, Rosenheck RA, Woods SW, (2003) Quantitative analysis of sponsorship bias in economic studies of antidepressants. Br J Psychiatry. 183: 498-506.
33. Jang S, Chae YK, Haddad T, Majhail NS, (2010) Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review. Breast Cancer Res Treat. 121 (2): 273-9.
34. Peura PK, Martikainen JA, Purmonen TT, Turunen JH, (2011) Sponsorship-Related Outcome Selection Bias in Published Economic Studies of Triptans: Systematic Review. Med Decis Making. Apr 13. [Epub ahead of print].
35. Rovira J, (2008) Transparency of economic evaluations of health technologies. Pharmacoeconomics. 26: 181-3.
36. Reinhardt UE, (1997) Making economic evaluations respectable. Soc Sci Med. 45: 555-62.
37. Clement FM, Harris A, Li JJ, Yong K, Lee KM, et al. (2009) Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA. 302: 1437-43.
38. Spanish Ministry of Health, Social Policy and Equality (2009) Quality Plan for the National Health System of Spain. Madrid Spanish Ministry of Health, Social Policy and Equality.
39. Gøtzsche PC, Kassirer JP, Woolley KL, Wager E, Jacobs A, et al. (2009) What should be done to tackle ghostwriting in the medical literature? PLoS Med. 6 (2): e23.
40. Bosch X, (2011) Exorcising ghostwriting... Ghostwriting could potentially have serious repercussions for science and should therefore be treated as research misconduct. EMBO Rep. 12 (6): 489-94.
41. Moffatt B, Elliott C, (2007) Ghost marketing: pharmaceutical companies and ghostwritten journal articles. Perspect Biol Med. 50 (1): 18-31.
42. Peiró S, Meneu R, Ortún V, Puig J, (2003) Possible problems of lack of objectivity, transparency, duplicate publication and authorship in the cost-effectiveness analysis of celecoxib. Gac Sanit. 17 (4): 342-4.
43. Howes F, Doyle J, Jackson N, Waters E, (2004) Evidence-based public health: The importance of finding 'difficult to locate' public health and health promotion intervention studies for systematic reviews. J Public Health (Oxf). 26: 101-4.
44. Hyder AA, Corluka A, Winch PJ, El-Shinnawy A, Ghassany H, et al. (2011) National policy-makers speak out: are researchers giving them what they need? Health Policy Plan. 26: 73-82.